UNSPSC 51383505: Oxametacin or oxamethacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8G02RSW5CM, chemically known as 1h-indole-3-acetamide, 1-(4-chlorobenzoyl)-n-hydroxy-5-methoxy-2-methyl- (9ci) but generally known as oxametacin, which bears US NIH Compound Identifier 33675. European Medicines Agency schedules Oxametacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09492MIG.

UNSPSC 51383505 Oxametacin or oxamethacin is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The three most recent opportunities tagged to this code involve naloxone procurement, a direct-to-manufacturer pharmacy initiative, and generic multi-source pharmaceuticals and OTC products — none of which are oxametacin or oxamethacin, an anti-inflammatory analgesic not commonly procured by state and local health systems through competitive bidding. The mismatch suggests the code sees little relevant recent activity in the state and local market, or that issuers are applying the code inconsistently to broader pharmaceutical procurement categories.

Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, requiring vendors to provide detailed product information and meet cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission issued an RFI (posted April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit managers. None of these solicitations target oxametacin specifically, indicating that firms pursuing opportunities under this code should verify the actual product need with the issuing body before investing in response preparation.